UPSC Daily Current Affairs – 3rd December 2025

UPSC Daily Current Affairs - 3rd December 2025

News at a Glance

National Action Plan on Antimicrobial Resistance (NAP-AMR 2.0)

Source: The Hindu

Relevance: Facts for Prelims, GS Paper – 2 – Government Policies & Interventions, GS Paper – 3 – Health

Important Key Concepts for Prelims and Mains:

For Prelims:

Antimicrobial resistance, Superbugs, Schedule H1, NDM-1 (New Delhi Metallo-beta-lactamase), Red Line Campaign, E. coli, Klebsiella and Pseudomonas.

For Mains:

Factors Fueling the Growing AMR Crisis in India, Measures that can be Adopted to Effectively Counter AMR Crises in India

Why in News?

Government has launched National Action Plan on Antimicrobial Resistance (NAP-AMR 2.0, 2025-29).
Article argues that its success depends on strong Centre–State coordination; otherwise, it may remain only a “technical document”.

What is Antimicrobial Resistance (AMR)

Definition: When microorganisms (bacteria, viruses, fungi, parasites) stop responding to medicines that once killed them.
Leads to “superbugs” – pathogens resistant to multiple drugs → routine infections become hard or impossible to treat.

How Microbes Become Resistant (Mechanisms)

Limiting uptake – alter cell wall, drug can’t enter.
Target modification – change the molecule the drug binds to.
Efflux pumps – “pumps” that throw the drug out of the cell.
Drug inactivation – enzymes (e.g. β-lactamases) that destroy the drug.

One Health Framework

Recognises that human, animal and environmental health are interconnected.
AMR spreads via hospitals, farms, aquaculture, soil, sewage, rivers, food chains, markets – not just clinics.

Background / Present Status

Silent pandemic & development threat: AMR now threatens decades of gains in health, agriculture & poverty reduction.
India faces AMR across:
- Hospitals & ICUs,
- Livestock & aquaculture,
- Pharma manufacturing hubs (e.g. Musi River, Hyderabad),
- Poor sanitation & untreated sewage.
Economic & social stakes:
- Treatment of resistant infections requires costly “last-resort” drugs (e.g. colistin, meropenem), long hospital stays and isolation → huge OOPE (39.4% of Total Health Expenditure).
- Resistant neonatal sepsis kills tens of thousands of newborns annually, undermining IMR goals.
- World Bank estimates up to 3.8% global GDP loss by 2050 due to AMR; India, as a high-burden country, is especially vulnerable.

Important Terms

Superbugs: Multi-drug-resistant organisms (e.g. carbapenem-resistant E. coli, Klebsiella, Pseudomonas).
NDM-1 (New Delhi Metallo-β-lactamase): Enzyme that makes bacteria resistant to powerful β-lactam antibiotics (incl. carbapenems).
Schedule H1: Drugs & Cosmetics Rules category; select antibiotics can be sold only on prescription, with pharmacy register & record-keeping.
Red Line Campaign: Red vertical line printed on antibiotic strips → “use only with doctor’s prescription” awareness tool.

What is NAP-AMR 1.0 & 2.0?

NAP-AMR 1.0 (2017) – Achievements & Limits

Achievements
- Put AMR on national agenda; adopted explicit One Health framing.
- Expanded lab networks, surveillance (ICMR-AMRSN, NCDC networks).
- Promoted antibiotic stewardship & multi-sectoral participation.
Limitations
- Weak State-level implementation:
  - Only a few States (Kerala, MP, Delhi, AP, Gujarat, Sikkim, Punjab) prepared formal State AMR Action Plans, fewer executed them well.
  - Most States continued with fragmented, sector-specific efforts, no functional One Health structure.
- Root cause: key levers of AMR (health services, pharmacy control, livestock, agriculture, food safety, waste regulation) lie within State jurisdiction; national guidance alone could not ensure implementation.

NAP-AMR 2.0 (2025–29) – Key Features

More implementation-oriented: Clearer timelines, responsibilities & resource planning.
Strengthened One Health:
- Greater focus on food-systems, waste management & environmental contamination.
- Integrated surveillance across human, veterinary, agriculture & environment.
Innovation push: Emphasis on rapid diagnostics, point-of-care tools, alternatives to antibiotics, better environmental monitoring.
Private sector engagement: Recognises that private hospitals & vets provide a large share of care; seeks their participation.
Governance:
- Inter-sectoral supervision under NITI Aayog via a Coordination & Monitoring Committee.
- Urges all States/UTs to set up State AMR Cells & State Plans; proposes a national dashboard.
Significance: Elevates AMR from a clinical issue to a national development priority.

Core Weakness of NAP-AMR 2.0

No binding Centre–State implementation mechanism:
- No statutory requirement for States to notify plans or establish AMR Cells.
- No regular joint review missions, no formal Centre–State AMR council, no NHM-linked financial incentives.
In a federal system where most determinants of AMR are State subjects, this is the “pivotal gap” → risk that NAP-AMR 2.0 stays a well-written document, not a live programme.

Factors Fueling the AMR Crisis in India

Clinical Misuse & “Pill-Popping Culture”

Broad-spectrum antibiotics prescribed for viral fevers due to lack of rapid diagnostics & patient expectations.
Schedule H1 enforcement is patchy; many pharmacies still sell strong antibiotics OTC.
Massive use of “Watch”-group antibiotics (≈59% of consumption, 2022); ~8 in 10 hospital entrants carry drug-resistant bacteria.
Post-COVID, habit of casually taking Dolo-650 etc. symbolises this mindset.

Livestock & Aquaculture Misuse (Growth-Promoter Epidemic)

Poultry & shrimp industries use critical drugs like colistin as growth promoters, not for treatment.
India is 4th largest animal-antibiotic consumer; use projected to rise ~82% by 2030.
Studies show 100% resistance to ampicillin in some shrimp samples from Kerala retail markets.

Pharmaceutical Pollution – “Hyderabad Model”

Untreated effluents from pharma hubs discharge high levels of active antibiotics into rivers (e.g. Musi River antibiotic levels ~1,000× safe limits).
These act as “evolutionary pressure cookers”, forcing bacteria to mutate into superbugs that spread through groundwater, irrigation and drinking water.

Irrational Fixed-Dose Combinations (FDCs)

Many unscientific “cocktail” drugs (multiple antibiotics, or antibiotic + vitamin) lead to sub-therapeutic exposure, speeding resistance.
Govt banned 156 FDCs in 2024 (including antibiotic cocktails) for “no therapeutic justification”, but others still circulate.

Sanitation & Wastewater Failures – “Scavenger Spread”

Poor sewage treatment lets resistant organisms like NDM-1-producing E. coli, Klebsiella, Pseudomonas leave hospitals and colonise municipal water.
Flawed toilet/sewage networks recycle these back into households, creating a continuous transmission loop.

Surveillance & Diagnostic Gaps

Data mainly from public tertiary hospitals & ICUs (ICMR-AMRSN, NARS-Net); rural & primary-care settings are blind spots.
Lack of affordable rapid tests → doctors prescribe empirically for safety → over-prescription.

Threats Posed by AMR

(A) Economic

Export & Trade Losses
- Seafood & shrimp exports face rejections in EU/US due to antibiotic residues.
- Poultry may be excluded from “antibiotic-free” global value chains.
Healthcare Cost Explosion & Poverty
- Resistant infections need costly drugs & long hospital stays.
- With 39.4% OOPE, one episode of resistant sepsis can impoverish families.
Productivity & GDP Loss
- Working-age population suffers prolonged illness; absenteeism rises.
- AMR could shave off up to 3.8% of global GDP by 2050; India’s demographic dividend is at risk.

(B) Social & Public Health

Return to Pre-Antibiotic Era
- Routine surgeries (C-sections, joint replacements, chemo) become high-risk.
- ~50,000+ newborn deaths/year from resistant sepsis undermine IMR targets.
Hospital Superbugs & MDR-TB
- Carbapenem-resistant E. coli, Klebsiella etc. now common in ICUs → almost no drugs left.
- India has highest MDR-TB burden; airborne, chronic and poverty-reinforcing.

(C) Environmental

Pharma effluents & agricultural run-off contaminate rivers, soil & groundwater with antibiotics and resistant organisms → classic One Health crisis.

Indian Government & Policy Response

NAP-AMR 1.0 (2017) and NAP-AMR 2.0 (2025-29) – national frameworks adopting One Health, surveillance & stewardship.
Delhi Declaration on AMR (2017) – inter-ministerial commitment.
Chennai Declaration – professional consensus of Indian medical societies on rational antibiotic use.
Schedule H1 – restricts sale of selected antibiotics; pharmacies must keep records.
Red Line Campaign – visible red line on antibiotic strips to discourage OTC use.
Ban on colistin in animal feed (critical last-resort drug).
FDC Ban (2024) – 156 irrational antibiotic combinations prohibited.
ICMR-AMRSN (2013) – national AMR surveillance across tertiary hospitals.
State innovations: e.g. Kerala’s PROUD & AMRITH initiatives, strict OTC enforcement, One-Health coordination.

What Must Be Done – Way Forward

Strengthen NAP-AMR 2.0 via Cooperative Federalism

National–State AMR Council
- Chaired by Union Health Minister + NITI Aayog; includes key State ministers & secretaries (health, animal husbandry, agriculture, environment).
- Platform for joint reviews, problem-solving and sharing best practices.
Mandatory State AMR Action Plans & Cells
- Formal letters from GoI / Chief Secretaries; notification with timelines & annual review.
NHM-Linked Conditional Grants
- Earmarked funds for labs, surveillance, infection prevention, stewardship & WASH; funding signals priority.
Integrated One-Health Dashboard
- Legally mandated data from human, veterinary, environment sectors; AI-based detection of “hotspots” linking farm antibiotic use with human outbreaks.

Fix Human-Health Drivers

Hub-and-Spoke Diagnostic Grid
- Tertiary-care labs as Hubs, PHCs/CHCs as Spokes.
- Samples transported with cold chain; digital antibiogram reports within 24 hrs → reduces blind prescriptions.
- Promote low-cost rapid tests (Assam’s DOSA, IIT lab-on-chip, etc.) to distinguish viral vs bacterial infections.
Behaviour Change Communication (BCC)
- Move beyond posters: use teachers, religious leaders, ASHAs to frame antibiotics as “precious, limited weapons”.
- Normalise that not every fever needs antibiotics; rest & time often suffice.
“Blue Envelope Protocol” for Antibiotics
- All antibiotic strips dispensed only in a distinct blue envelope with message: “Complete full course; incomplete doses create superbugs.”
- Makes antibiotics psychologically distinct from routine pills and discourages storage for casual future use.

Address Animal, Food & Environment Pathways

“Antibiotic-Smart Villages / WASH-First Defence”
- 100% clean water, toilets, sewage treatment in pilot clusters → reduced diarrhoea & typhoid → lower antibiotic demand.
Green-Pharma Procurement
- Govt tenders to favour companies with Zero Liquid Discharge (ZLD) and real effluent treatment → profits tied to clean production.
Farm-to-Fork Traceability (Poultry & Aquaculture)

Blockchain / QR-code system that records feed, vaccines, and antibiotic-use history; consumers can see if meat/eggs are “antibiotic-free” → pushes industry towards safer practices.

Subsidised Animal Vaccines & Better Biosecurity

Vaccinating poultry & livestock significantly cuts disease → fewer antibiotics used.

Kerala-Style Enforcement Nationwide

Strict ban on OTC sale of antibiotics + regular inspections; multi-sectoral One Health committees at district level.

Conclusion

AMR is not just a medical issue; it is a multi-dimensional development crisis that threatens food security, exports, public health and India’s demographic dividend. India has taken bold steps — from banning colistin and irrational FDCs to launching NAP-AMR 2.0 under a One Health framework. But without hard Centre–State coordination, sustained funding, and behaviour change from wards to farms to factories, these measures will fall short.

If India can now build a coordinated, accountable, One-Health implementation architecture, it can both protect its people and emerge as a global leader in the fight against superbugs. If not, we risk sliding back into a pre-antibiotic era where routine infections once again become potential death sentences.

UPSC PYQ

Which of the following are the reasons for the occurrence of multi-drug resistance in microbial pathogens in India? (2019)

Genetic predisposition of some people
Taking incorrect doses of antibiotics to cure diseases
Using antibiotics in livestock farming
Multiple chronic diseases in some people

Select the correct answer using the code given below.

(a) 1 and 2

(b) 2 and 3 only

(d) 2, 3 and 4

Ans: (b)

CARE MCQ

Q. Consider the following sectors:

Pharmaceutical manufacturing
Livestock and aquaculture
Wastewater and sanitation systems
Intensive Care Units (ICUs)

In the context of India’s AMR challenge, which of the above are recognised as major “primary drivers” in NAP-AMR 2.0’s One Health framework?

A. 1, 2 and 3 only
B. 1 and 4 only
C. 2, 3 and 4 only
D. 1, 2, 3 and 4

Answer: A

Explanation:

NAP-AMR 2.0 identifies pharma pollution, livestock overuse, and wastewater contamination as primary community-level drivers of AMR. ICU resistance emerges downstream; the main drivers occur outside hospitals.

Why does India need bioremediation?

Source: The Hindu

Relevance: GS-III (Environment, Pollution, Biotechnology

Important Key Concepts for Prelims and Mains:

For Prelims:

In Situ Bioremediation, Ex Situ Bioremediation, GM Microbes / Synthetic Biology Bioaugmentation & Biostimulation, CSIR–NEERI / DBT Clean Technology Programme

For Mains:

Sustainable Waste Remediation, Bioremediation–Biotechnology Convergence Low-cost, Nature-based Solutions (NbS), Regulatory & Biosafety Gaps, Pollution Hotspots & Hazardous Site Restoration

Why in News?

India is facing rising environmental degradation from untreated sewage, industrial effluents, oil spills, and chemical pollutants. Since conventional clean-up methods are costly and energy-intensive, bioremediation has gained prominence as a sustainable and low-cost solution. Recent initiatives by DBT, CSIR–NEERI, and IITs—including microbial, nanotech, and biotechnology-based clean-up tools—have brought bioremediation into renewed national focus.

What is Bioremediation?

Bioremediation means “restoring life using biology.”
It uses microorganisms like bacteria, fungi, algae, and plants to transform or break down toxic pollutants such as:

Oil spills
Plastics
Pesticides
Heavy metals
Industrial chemicals
Sewage contaminants

These organisms metabolise pollutants as food, converting them into non-toxic by-products (water, CO₂, organic acids). In some cases, they convert hazardous metals into stable, less harmful forms.

Types of Bioremediations

1. In Situ Bioremediation

Cleaning contaminated sites on the spot.
Example: Oil-eating bacteria sprayed directly on an ocean spill.

2. Ex Situ Bioremediation

Removing contaminated soil/water, treating it in a facility, then returning it.
Example: Soil washing units for pesticide-contaminated farmland.

How Modern Biotechnology Enhances Bioremediation

Traditional microbiology is now combined with cutting-edge biotechnology to improve pollutant removal.

Key Innovations

Genetically modified (GM) microbes that degrade plastics or oil residues more efficiently.
Synthetic biology–based biosensors that change colour/fluoresce when toxins are detected.
Nanobiotech materials, such as cotton-based nanocomposites developed by IIT researchers, to mop up oil spills.

These approaches enable high precision, faster degradation, and early detection of contaminants.

Why India Needs Bioremediation

India faces multi-dimensional environmental challenges:

1. Pollution Hotspots

Rivers like Ganga and Yamuna receive massive loads of untreated sewage and industrial waste daily.

2. Oil Leaks & Hazardous Sites

Frequent industrial leaks, refinery spills, and coal mining wastelands threaten ecosystems.

3. Agricultural Contamination

Pesticides, fertilisers, and heavy metals accumulate in soils.

4. Cost and Sustainability Issues

Mechanical/chemical clean-up methods are:

expensive,
energy-heavy,
create secondary waste.

Bioremediation is cheaper, scalable, and eco-friendly, ideal for India’s polluted landscapes.

5. India’s Biodiversity Advantage

India’s diverse microbes thrive in:

high heat,
salinity,
acidity,
unique soil ecosystems.

This makes indigenous species more effective than imported strains.

Where Does India Stand Today?

Government Initiatives

DBT Clean Technology Programme
Funds microbial remediation research and industry collaborations.
CSIR–NEERI
Leads major projects on wastewater treatment, oil-spill cleaning, and microbial remediation.

Academic Research

IIT teams have developed nanocomposite mats to absorb oil spills.
Indian scientists have identified bacteria capable of degrading pesticides, dyes, and petrochemicals.

Startups & Industry

BCIL, Econirmal Biotech and others offer microbial solutions for wastewater, landfills, and agriculture.

Challenges

1. Technical

Lack of site-specific microbial data
Complexity of multi-pollutant environments
Performance variability in real field conditions

2. Regulatory

No unified national bioremediation standards
Lack of biosafety rules for GM microbes

3. Institutional

Limited trained personnel
Weak coordination between municipalities, industries & labs

4. Public Perception

Fear of releasing microorganisms into the environment
Low awareness about scientific safety mechanisms

What Other Countries Are Doing

Japan integrates microbial and plant-based remediation into city waste systems.
EU runs cross-nation bioremediation projects to clean oil spills and mining sites.
China uses GM bacteria to reclaim industrial wastelands under its soil pollution control law.

India can adopt similar large-scale, integrated strategies.

Opportunities and Risks

Opportunities

Restoring polluted rivers and industrial sites
Reclaiming mining wastelands
Job creation in biotech, environmental engineering, waste management
Support for national missions: Swachh Bharat, Namami Gange, Green Hydrogen, Circular Economy

Risks

Uncontrolled spread of GM microbes in open environments
Ecological disturbances due to poor monitoring
Lack of biosafety infrastructure
Public mistrust without transparent communication

Strict regulatory oversight is essential.

The Way Forward

1. National Bioremediation Standards

Create unified guidelines for microbial use, safety, testing & deployment.

2. Regional Bioremediation Hubs

Connect universities, local governments, industries, and DBT-BIRAC programs.

3. Indigenous Microbe Banks

Catalogue India’s native microbial species suited for different climates & contaminants.

4. Biosafety Strengthening

Develop monitoring labs, certification mechanisms, and GM organism containment norms.

5. Public Engagement

Communicate that not all microbes are harmful—many are crucial to environmental revival.

UPSC PYQ

Q. Consider the following statement about bioremediation: (UPSC -2017)

It is a technique for cleaning up pollution by enhancing the same biodegradation process that occurs in nature.
Any contaminant with heavy metals such as cadmium and lead can be readily and completely treated by bioremediation using microorganisms.
Genetic engineering can be used to create microorganisms specifically designed for bioremediation.

Select the correct answer using the code given below:
(a) 1 only
(b) 2 and 3 only
(c) 1 and 3 only
(d) 1, 2 and 3

Correct Answer: (c) 1 and 3 only

Explanation

Statement 1: “Bioremediation enhances natural biodegradation to clean pollution.” – Correct

Bioremediation relies on microorganisms, fungi, algae, or plants to accelerate natural degradation processes.
It breaks down pollutants like oils, pesticides, hydrocarbons, and some toxic chemicals into harmless by-products (CO₂, water, organic acids).

Statement 2: “Heavy metals like cadmium and lead can be completely treated by bioremediation.” – Incorrect

Heavy metals cannot be fully degraded (they are elements).
Bioremediation can transform, immobilize, or reduce toxicity of heavy metals, but cannot completely remove or biodegrade them.
Hence the statement claiming complete treatment is wrong.

Statement 3: “Genetic engineering can create microbes for bioremediation.” – Correct

Modern biotechnology and synthetic biology allow scientists to engineer microorganisms to:
- degrade tough pollutants (plastics, oil residues)
- detect toxins (biosensing)
- survive harsh conditions (high salinity, acidity, temperature)
This aligns with advanced bioremediation methods described in the article (GM microbes, engineered enzymes).

CARE MCQ

Q .The process of using microbes to treat areas of land or sea that have been contaminated by pesticides, oil or solvents is known as:

(a) Eutrophication
(b) Nitrification
(c) Ammonification
(d) Bioremediation

Correct Answer: (d) Bioremediation

Explanation

Bioremediation refers to the use of microorganisms such as bacteria, fungi or algae to detoxify polluted environments.
These microbes break down harmful pollutants (oil, pesticides, solvents, heavy metals) into harmless substances like CO₂, water, or simple organic acids.
It can be in situ (treating pollution at the site) or ex situ (removing contaminated material and treating it elsewhere).

Top of Form

Bottom of Form